Eric Lefkofsky Uses a Molecular Database to Fight Cancer

Financial Advisor, Health Care

One of the most fascinating things about cancer is its uniqueness. For the longest time, doctors and researchers simply categorized cancer by which body part it originated from. If the cancer started in the lungs and then spread to other parts of the body, it was known as lung cancer. But researchers are finding that cancer is much more complicated and nuanced and more information click here.

Each cancer has its own unique DNA. That DNA interacts with the patient’s DNA. This creates a cancer that is unique to each individual. Simply categorizing cancer by which body part it originated from is very obsolete with this new molecular understanding of the disease.

This is where Eric Lefkofsky and his company Tempus comes in. Eric Lefkofsky started the company after learning his own wife was diagnosed with cancer. He soon found that patient records were woefully incomplete when it comes to the disease. Tempus is striving to create the most complete database of cancer patient records ever assembled and the company wants to include molecular information and learn more about Eric.

Eric Lefkofsky has already made his millions in the tech world. He graduated from the University of Michigan and earned a law degree in just two years. He turned his attention to the burgeoning dot-com boom and he did well for himself. Perhaps his most popular achievement was the co-founding of Groupon.

To date, he has already donated millions to cancer research and he is not looking for a financial return with Tempus. He is simply compiling the most extensive molecular database of cancer in hopes of ridding humankind of the disease.

Tempus ran into a few problems early on. The medical community did a poor job of keeping cancer patient records and many of the records were handwritten. Tempus was able to come up with software that scanned the handwriting to be turned into digitized text for the database and Eric’s lacrosse camp.

Now the company is focusing on the molecular side of cancer. An algorithm is capable of scanning a patient’s DNA and running it against the database to see if there are any effective treatments for that particular type of cancer and